JP2013534256A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534256A5
JP2013534256A5 JP2013525003A JP2013525003A JP2013534256A5 JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5 JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013534256 A5 JP2013534256 A5 JP 2013534256A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
compound according
acceptable salt
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013525003A
Other languages
English (en)
Japanese (ja)
Other versions
JP6250394B2 (ja
JP2013534256A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048472 external-priority patent/WO2012024616A1/en
Publication of JP2013534256A publication Critical patent/JP2013534256A/ja
Publication of JP2013534256A5 publication Critical patent/JP2013534256A5/ja
Application granted granted Critical
Publication of JP6250394B2 publication Critical patent/JP6250394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013525003A 2010-08-19 2011-08-19 軽度の認知障害(mci)および関連障害の処置方法 Active JP6250394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
US61/401,907 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016160482A Division JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2013534256A JP2013534256A (ja) 2013-09-02
JP2013534256A5 true JP2013534256A5 (enExample) 2014-10-09
JP6250394B2 JP6250394B2 (ja) 2017-12-20

Family

ID=45605447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013525003A Active JP6250394B2 (ja) 2010-08-19 2011-08-19 軽度の認知障害(mci)および関連障害の処置方法
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害(mci)および関連障害の処置方法

Country Status (10)

Country Link
US (1) US10449177B2 (enExample)
EP (1) EP2605655B1 (enExample)
JP (2) JP6250394B2 (enExample)
AU (1) AU2011291506B2 (enExample)
BR (1) BR112013003847A8 (enExample)
CA (1) CA2808630A1 (enExample)
DK (1) DK2605655T3 (enExample)
ES (1) ES2705027T3 (enExample)
MX (1) MX353096B (enExample)
WO (1) WO2012024616A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
US20150209306A1 (en) 2012-08-07 2015-07-30 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US9993472B2 (en) 2014-01-28 2018-06-12 Unity Biotechnology, Inc. Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
ES2960625T3 (es) 2014-03-21 2024-03-05 Alzheon Inc Compuestos para uso en el tratamiento de la enfermedad de Alzheimer en pacientes de ApoE4+/+
AU2016220049C1 (en) 2015-02-18 2021-02-25 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
JP2018516901A (ja) * 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーSynaptec Development Llc アミロイドβのガランタミンクリアランス
EP3347002B1 (en) 2015-09-10 2023-06-07 Alzheon, Inc. Treatment of alzheimer's disease in a particular patient population
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
AU2017264931B2 (en) 2016-05-12 2021-02-04 Buck Institute For Research On Aging Compounds to promote normal processing of APP
JP7790686B2 (ja) 2017-01-03 2025-12-23 バイオアトラ インコーポレイテッド 老化細胞の処置のためのタンパク質療法
MX2021000395A (es) 2018-07-11 2021-05-12 Rubedo Life Sciences Inc Composiciones senolíticas y usos de las mismas.
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
JP7618230B2 (ja) 2019-07-25 2025-01-21 学校法人東京理科大学 精神・神経系の疾患又は症状を治療し、予防し又は改善する剤

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス ノバ インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
DE69233109T2 (de) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
AU5002399A (en) 1998-07-17 2000-02-07 National Broach And Machine Company Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
ES2318902T3 (es) 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
JP4288263B2 (ja) 2002-10-25 2009-07-01 コレジウム ファーマシューティカル, インク. p−ヒドロキシ−ミルナシプランの立体異性体およびその使用方法
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CA2557541C (en) 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
US7794403B2 (en) 2004-04-21 2010-09-14 Mear Holding B.V. System for measuring pulsatile vascular resistance
US8470846B2 (en) * 2004-04-30 2013-06-25 National University Corporation Chiba University Remedy for psychoneurotic diseases
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
JP2008524332A (ja) 2004-12-20 2008-07-10 コレジウム ファーマシューティカル, インク. 睡眠傷害のための医薬組成物
DE602005019210D1 (de) 2004-12-23 2010-03-18 Xenoport Inc Von serinaminosäure abgeleitete prodrugs von propofol, zusammensetzungen, anwendungen und kristalline formen davon
US20090156581A1 (en) 2005-04-15 2009-06-18 Board Of Trustrees Of Michigan State University Aminergic pharmaceutical compositions and methods
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1993542A1 (en) 2006-03-01 2008-11-26 Galderma Research & Development, S.N.C. Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
WO2008074896A1 (en) 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
CN101742991A (zh) 2007-05-03 2010-06-16 杰克·L·阿比瑟 和厚朴酚类似物及其在治疗癌症中的用途
US20090163451A1 (en) 2007-11-16 2009-06-25 Frank Porreca Methods for treating visceral pain
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
US20110118189A1 (en) 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
KR101653707B1 (ko) 2008-05-29 2016-09-02 알바니 몰레큘라 리써치, 인크. 5-ht3 수용체 조절제, 이의 제조 방법, 및 그의 용도
US8604087B2 (en) 2008-09-25 2013-12-10 Bioland Ltd. Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol
BRPI0914080A2 (pt) 2008-10-08 2015-10-27 Bioplus Life Sciences Pvt Ltda "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo"
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
US9017718B2 (en) 2009-05-21 2015-04-28 Bionex Pharmaceuticals Llc Dual and single layer dosage forms
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US20150030683A1 (en) 2012-02-18 2015-01-29 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Similar Documents

Publication Publication Date Title
JP7398836B2 (ja) R-ケタミンおよびその塩の医薬品としての応用
JP2017075173A5 (enExample)
JP2015510941A5 (enExample)
JP2008520589A5 (enExample)
JP2018035197A5 (enExample)
JP2021525729A5 (enExample)
JP2013533287A5 (enExample)
JP2012530723A5 (enExample)
US10342807B2 (en) Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201400183A1 (ru) Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства
JP2019513814A5 (enExample)
JP2016510343A5 (enExample)
CA3184122A1 (en) Methods of treating proteinopathies
RU2016102092A (ru) Тауроурсодезоксихолевая кислота (tudca) для применения в лечении нейродегенеративных нарушений
MX2008000249A (es) Combinaciones de eszopiclona y o-desmetilvenlafaxina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y cognitivos.
JP2020523342A5 (enExample)
JP2009526834A5 (enExample)
WO2011058262A1 (fr) Médicament inhalable à base de xénon pour traiter ou pour prévenir les dyskinésies induites
JP2009178162A5 (enExample)
CA3138389A1 (en) Rebamipide for use in prevention and/or treatment of synucleinopathies
JP2016528171A5 (enExample)
JP2020527172A5 (enExample)
RU2019101210A (ru) Производное оксазина для применения в предупреждении болезни альцгеймера у пациентов, находящихся в группе риска